Nationwide Children’s Hospital joins TriNetX

To help create clinical trials, Nationwide Children’s Hospital, pediatric hospital Columbus, Ohio, has signed an agreement to join TriNetX, a software company in Cambridge, Massachusetts.

TriNetX is a network of healthcare organizations that represent more than 57 million patients, biopharmaceutical companies and contract research organizations around the world, according to a statement from the company. Together they work to design clinical trials and quickly bring new therapies to the market.

Nationwide is one of the country’s largest nonprofit pediatric healthcare systems. They provide wellness, preventive, diagnostic, treatment and rehabilitative care for youths ranging from infants to adolescents.

"Nationwide Children's is now a member of a rapidly expanding and first-of-its-kind network of pediatric hospitals, general medicine health systems, cancer centers, biopharma and CROs who are all leveraging TriNetX in ways that foster better collaboration and efficiency in clinical research," said Gadi Lachman, CEO of TriNetX, in a statement.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.